Conference Coverage

WCD: Pramocaine is a common contact sensitizer


 

AT WCD 2015

References

VANCOUVER – Pramocaine, a topical anesthetic long used in many OTC anti-itch preparations, turns out to itself be a common cause of contact sensitization, Dr. Mariam Abbas reported at the World Congress of Dermatology.

Pramocaine, also known as pramoxine, is an ingredient in Gold Bond cream, some forms of calamine lotion, hemorrhoid relief products, and other OTC antipruritic agents. It’s not available in commercial patch test kits, so Dr. Abbas created a test material comprised of 2% pramocaine in petrolatum.

Seven of 232 patients (3%) referred to a university patch test clinic and who underwent testing to pramocaine along with recognized contact sensitizers showed a clear positive response to pramocaine at 96 hours. The reactions were clinically relevant, according to Dr. Abbas of the University of Alberta, Edmonton.

That 3% positive rate is in the range of published figures for such well-known problem contact sensitizers as neomycin, thiuram mix, and Balsam of Peru.

Dr. Mariam Abbas reported having no financial conflicts regarding this study, conducted free of commercial support.

bjancin@frontlinemedcom.com

Recommended Reading

Skin patch therapy for peanut allergy wins plaudits
MDedge Pediatrics
Early consumption of peanuts can induce tolerance in high-risk children
MDedge Pediatrics
Beware common management pitfalls in severe refractory pediatric AD
MDedge Pediatrics
SLIT: Guidelines in progress and practical concerns
MDedge Pediatrics
When to use SLIT and SCID in atopic dermatitis
MDedge Pediatrics
Pimecrolimus cream safe, effective for atopic dermatitis in young children
MDedge Pediatrics
Boron-based cream shows promise for pediatric atopic dermatitis
MDedge Pediatrics
Aspirin desensitization making headway in U.S.
MDedge Pediatrics
Safely patch test children for contact dermatitis
MDedge Pediatrics
WCD: Topical tofacitinib hits marks in atopic dermatitis
MDedge Pediatrics